Johnson & Johnson (NYSE:JNJ) Sees Significant Growth in Short Interest

Johnson & Johnson (NYSE:JNJGet Free Report) saw a significant growth in short interest in May. As of May 31st, there was short interest totalling 19,930,000 shares, a growth of 14.3% from the May 15th total of 17,430,000 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average daily volume of 7,620,000 shares, the short-interest ratio is presently 2.6 days.

Johnson & Johnson Trading Down 0.3 %

Shares of NYSE:JNJ traded down $0.40 during trading hours on Tuesday, hitting $145.55. 684,751 shares of the company’s stock traded hands, compared to its average volume of 7,311,045. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The business has a fifty day moving average price of $148.27 and a 200-day moving average price of $154.65. The firm has a market capitalization of $350.29 billion, a P/E ratio of 9.10, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the business earned $2.68 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s payout ratio is presently 30.92%.

Institutional Trading of Johnson & Johnson

A number of large investors have recently modified their holdings of the company. NBW Capital LLC boosted its holdings in shares of Johnson & Johnson by 22.3% in the first quarter. NBW Capital LLC now owns 1,580 shares of the company’s stock valued at $250,000 after purchasing an additional 288 shares during the period. Keynote Financial Services LLC purchased a new stake in Johnson & Johnson during the first quarter worth $1,612,000. OMC Financial Services LTD purchased a new stake in Johnson & Johnson during the first quarter worth $2,200,000. EverSource Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 64.7% during the first quarter. EverSource Wealth Advisors LLC now owns 14,509 shares of the company’s stock worth $2,098,000 after buying an additional 5,701 shares during the period. Finally, DekaBank Deutsche Girozentrale lifted its holdings in Johnson & Johnson by 2.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 4,483,071 shares of the company’s stock worth $709,442,000 after buying an additional 86,655 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. The Goldman Sachs Group assumed coverage on Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, May 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday. cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Monday, June 10th. Finally, HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Eight equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from, Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $174.07.

Get Our Latest Analysis on JNJ

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.